Compare Hims and Hers Health Inc (HIMS) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Intel Corp — how do they compare? Hims and Hers Health Inc trades at $29.04 (market cap $6.55B), while Intel Corp trades at $106.17 (market cap $566.04B). The key difference: Intel Corp is far larger — about 86.4× Hims and Hers Health Inc's market cap, and Intel Corp pays a 2.24% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Intel Corp for 116 Days on average.
| HIMS | INTC | |
|---|---|---|
Market Cap | $6.55B | $566.04B |
Volume | 14,842,814 | 118,475,837 |
Sector | Health | Technology |
52-Week High | $62.76 | $140.94 |
52-Week Low | $14.52 | $33.62 |
Typical Hold Time | 21 Days | 116 Days |
Enterprise Value | $7.25B | $586.85B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
Intel (INTC) trades at $113.12, up 0.55% on the day, with a bullish technical signal supported by moving averages. Recent earnings beats and a 222% stock surge in 2026 reflect strong AI momentum and foundry growth, though negative net income and high valuation ratios signal caution. The company's cash flow improved in 2025, but competitive pressures and margin challenges persist.
The outlook hinges on Intel's foundry turnaround gaining traction, with revenue growth and external customer adoption as key catalysts. Risks include intense competition, high debt, and execution uncertainty. Analyst consensus is mixed, with a hold rating dominant, suggesting cautious optimism amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
